Artiva Biotherapeutics: CEO Fred Aslan sold 23,463 shares

What happened Fred Aslan, CEO, sold 23,463 shares in an open-market sale at $7.20 per share on Oct 6, 2026, disposing of $168,880, according to the Form 4 filing.

Key details

• Transaction date and price: Oct 6, 2026 — sale of 23,463 shares at a reported price of $7.20 per share. The filing also reports a weighted average sale price of $7.1977 and a price range of $6.92 to $7.36.
• Shares owned after the transaction: the filing does not report shares owned after the transaction in the provided excerpt.
• Footnotes: F1 — the transactions occurred pursuant to a Rule 10b5-1 plan adopted May 13, 2026. F2 — the filing states the weighted average sale price was $7.1977 and the range was $6.92 to $7.36; full breakdown by price is available upon request.
• Filing date timeliness: the Form 4 was filed on Oct 7, 2026, reporting the Oct 6, 2026 transaction (no late filing is indicated in the filing).

Why it may matter

• The filing indicates an open-market sale executed under a Rule 10b5-1 plan; it does not indicate an option exercise, award, or gift.
• The filing does not show why the insider traded or why the company acted.